Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

NCTID	NCT04125732 (View at clinicaltrials.gov)
Description	The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization). (Show More)
Indication	Refractory Angina
Compound Name	Encoberminogene rezmadenovec (XC001)
Sponsor	XyloCor Therapeutics, Inc.
Funder Type	Industry
Status	Completed
Enrollment Count	41

Target Gene/Variant	VEGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intramyocardial
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	Ad5
Editor Type
Dose 1	1 x 10^9 vp
Dose 2	1 x 10^10 vp
Dose 3	4 x 10^10 vp
Dose 4	1 x 10^11 vp (Expansion Dose)
Dose 5

No.of Trial Sites	16
Locations	United States

Has US IND	True
Recent Updates